January 13, 2025
CONTACT:
Jud Hall
877.443.4006
Dallas, TX- AIC, a division of AIS Healthcare, now offers ALYGLO™, manufactured by GC Biopharma, for the treatment of patients with primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).
The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized infusion services to patients in their home or in an infusion suite setting. This new immunoglobulin (Ig) therapeutic option will expand AIC’s ability to better serve PI patients.
“We are excited to add ALYGLO™ to our expansive list of Ig infusion therapies,” said Jud Hall, President of AIC. “AIC is proud to partner with GC Biopharma to offer this extra-purified IVIg replacement therapy as another treatment option to patients nationwide”, added Stan Singley, Vice President of Trade & Procurement.”
Approved by the U.S Food and Drug Administration in 2023, ALYGLO™ is now available at all AIC locations (Valdosta, GA; Birmingham, AL; Panama City, FL; Cockeysville, MD; and Dallas, TX).
Like all AIC patients, those with PI will receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, home infusion nurses, RN clinical review specialists, and patient access specialists to provide support throughout the treatment process.
For physicians, AIC is more than a specialty pharmacy. We are a full-service care delivery partner, and we have contracts with multiple immunoglobulin suppliers, like GC Biopharma. These contracts help us ensure prescribed therapies are always in stock. We also work directly with patients, insurance companies, and physician offices to secure all needed insurance authorizations and approvals.
AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other infusion services providers.
Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/
As the leading provider of infusion care solutions and targeted drug delivery, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com.
GC Biopharma is a global biopharmaceutical company, and a pioneer in the field of specialty pharmaceuticals. It is committed to improving the lives of people around the world and has built a global network of professionals and facilities to make this vision a reality.
GC Biopharma manufactured its first plasma-derived therapy in South Korea in 1971. Since then, the company has grown to become one of the top pharmaceutical manufacturers of plasma therapeutics in the world, distributing to more than 50 countries.
Throughout its history, which spans more than half a century, GC Biopharma has focused heavily on plasma-derived drug products. With one of the largest plasma manufacturing facilities in the world, it is devoted to developing new drugs to achieve its mission and vision.